News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?
Khalis Mustafayev/LinkedIn
Dec 1, 2024, 08:51

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

KhalisMustafayev, Research Scientist at Miami Cancer Institute, shared on X:

“Are BCR::ABL1 TKIs safe for cancer patients with chronic Hepatitis C? Our latest study explores the virologic effect and hepatotoxicity of BCR::ABL1 TKIs.”

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study – ScienceDirect

Authors: Khalis Mustafayev, Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa C. Ghayas, Ravin Ratan, Naveen Pemmaraju, Harrys A. Torres

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

cancer Courtney D. DiNardo Eduardo Yepez Guevara Elias Jabbour Harrys A. Torres hepatitis C Issa C. Ghayas Khalis Mustafayev Naveen Pemmaraju OncoDaily Oncology Ravin Ratan
Special Coverage
Blog
Jan 6, 2025, 11:39
Sami (Papacek) Mansfield: The next cohort of the My Lifestyle Shift program
Blog
Jan 6, 2025, 11:35
Biagio Ricciuti: TROPICS-03 trial - Sacituzumab Govitecan in 2L extensive stage SCLC
Insight
Jan 6, 2025, 11:11
Akhil Santhosh: Switching 5 FU for docetaxel in the Tp-EXTREME trial
Science
Jan 6, 2025, 11:03
Myeloma Paper of the Day, January 6th, suggested by Robert Orlowski
Blog
Jan 6, 2025, 10:47
Tata Mayaah Eveline: Humanity at Heart International stands in solidarity with all those impacted by cervical cancer
Blog
Jan 6, 2025, 10:45
Megan-Claire Chase: Warrior Megsie… the SUPERHERO
Science
Jan 6, 2025, 10:42
Malte Roerden: How different immune evasion mechanisms interfere with immunoediting of evolving tumors
Blog
Jan 6, 2025, 10:41
Roupen Odabashian: The second lesson in my series on using AI to enhance learning
Blog
Jan 6, 2025, 10:39
Sachin H. Jain: In 2025, I urge you to start seeing things clearly
Positive
Jan 6, 2025, 10:36
As we begin 2025, we express our deepest gratitude to all of our supporters - The Max Foundation
Insight
Jan 6, 2025, 10:31
Immunosuppression in the Lung, New Mathematical Models and More - AACR
Insight
Jan 6, 2025, 10:15
Nelson Dusetti: New therapeutic avenues for new therapeutic avenues for improving PDAC treatment